Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden flag Sweden · Delayed Price · Currency is SEK
5.65
+0.12 (2.17%)
Aug 14, 2025, 2:00 PM CET

Egetis Therapeutics AB Revenue

Egetis Therapeutics AB had revenue of 12.70M SEK in the quarter ending March 31, 2025, with 4.96% growth. This brings the company's revenue in the last twelve months to 46.70M, down -25.76% year-over-year. In the year 2024, Egetis Therapeutics AB had annual revenue of 46.10M, down -19.97%.

Revenue (ttm)
46.70M
Revenue Growth
-25.76%
P/S Ratio
42.54
Revenue / Employee
1.23M
Employees
40
Market Cap
1.99B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202446.10M-11.50M-19.97%
Dec 31, 202357.60M35.00M154.87%
Dec 31, 202222.60M-15.60M-40.84%
Dec 31, 202138.20M-2.46M-6.05%
Dec 31, 202040.66M-41.90M-50.75%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Swedish Orphan Biovitrum AB 26.97B
Sectra AB 3.31B
Getinge AB 35.50B
Medicover AB 25.22B
Asker Healthcare Group AB 15.88B
Camurus AB 2.27B
Bonesupport Holding AB 1.06B
AddLife AB 10.44B
Revenue Rankings